{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:10:26Z","timestamp":1791144626434,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1097\/fpc.0b013e32835693f7","type":"journal-article","created":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T07:11:53Z","timestamp":1344582713000},"page":"716-724","source":"Crossref","is-referenced-by-count":63,"title":["Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson\u2019s disease"],"prefix":"10.1097","volume":"22","author":[{"given":"Monika","family":"Bia\u0142ecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Kurzawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Roszmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Robowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia J.","family":"Sitek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna","family":"Honczarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Gorzkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Budrewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Jarosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Go\u0142\u0105b-Janowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Koziorowska-Gawron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Dro\u017adzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"S\u0142awek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210214","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/jnnp.2009.198689","article-title":"The estimated life expectancy in community cohort of Parkinsons disease patients, with and without dementia, compared with the UK population.","volume":"81","author":"Hobson","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-2-20210214","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/mds.23919","article-title":"Cognitive impairment in nondemented Parkinsons disease.","volume":"26","author":"Barone","year":"2011","journal-title":"Mov Disord"},{"key":"R3-2-20210214","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","article-title":"The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinsons disease and Parkinsons disease dementia.","volume":"120","author":"Schulz-Schaeffer","year":"2010","journal-title":"Acta Neuropathol"},{"key":"R4-2-20210214","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.parkreldis.2008.03.005","article-title":"Impaired cognitive performance in Parkinsons disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.","volume":"15","author":"Jokinen","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"R5-2-20210214","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2009.05118.x","article-title":"The progression of pathology in Parkinsons Disease.","volume":"1184","author":"Halliday","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R6-2-20210214","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00002093-199910000-00009","article-title":"Progression of regional neuropathology in Alzheimers disease and normal elderly: findings from the NUN Study.","volume":"13","author":"Wolf","year":"1999","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"R7-2-20210214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-8-26","article-title":"Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimers disease.","volume":"8","author":"Grammas","year":"2011","journal-title":"J Neuroinflammation"},{"key":"R8-2-20210214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399411001918","article-title":"Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases.","volume":"13","author":"Grammas","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"R9-2-20210214","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.22522","article-title":"Homocysteine and cognitive impairment in Parkinsons disease: a biochemical, neuroimaging, and genetic study.","volume":"24","author":"Rodriguez-Oroz","year":"2009","journal-title":"Mov Disord"},{"key":"R10-2-20210214","doi-asserted-by":"crossref","first-page":"113","DOI":"10.55782\/ane-2007-1639","article-title":"Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimers and Parkinsons diseases.","volume":"67","author":"Dorszewska","year":"2007","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"R11-2-20210214","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.febslet.2006.04.088","article-title":"Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia.","volume":"580","author":"Obeid","year":"2006","journal-title":"FEBS Lett"},{"key":"R12-2-20210214","doi-asserted-by":"crossref","first-page":"38382","DOI":"10.1074\/jbc.M110.146258","article-title":"Homocysteine, another risk factor for Alzheimer disease, impairs apolipoprotein E3 function.","volume":"285","author":"Minagawa","year":"2010","journal-title":"J Biol Chem"},{"key":"R14-2-20210214","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7326\/0003-4819-139-5_Part_2-200309021-00012","article-title":"Gene-diet interactions in brain aging and neurodegenerative disorders.","volume":"139","author":"Mattson","year":"2003","journal-title":"Ann Intern Med"},{"key":"R15-2-20210214","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","article-title":"Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.","volume":"66","author":"Postuma","year":"2006","journal-title":"Neurology"},{"key":"R16-2-20210214","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1212\/01.WNL.0000055899.24594.8E","article-title":"Effects of L-dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status.","volume":"60","author":"Miller","year":"2003","journal-title":"Neurology"},{"key":"R18-2-20210214","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ajmg.b.30700","article-title":"Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels.","volume":"147B","author":"Tunbridge","year":"2008","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R19-2-20210214","first-page":"272","article-title":"Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinsons disease.","volume":"43","author":"Bialecka","year":"2009","journal-title":"Neurol Neurochir Pol"},{"key":"R20-2-20210214","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0165-6147(00)01675-8","article-title":"Biological and clinical implications of the MTHFR C677T polymorphism.","volume":"22","author":"Ueland","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"R21-2-20210214","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1212\/WNL.55.3.437","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.","volume":"55","author":"Yasui","year":"2000","journal-title":"Neurology"},{"key":"R22-2-20210214","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jns.2006.05.040","article-title":"Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinsons disease, with and without levodopa therapy.","volume":"248","author":"Todorovic","year":"2006","journal-title":"J Neurol Sci"},{"key":"R23-2-20210214","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","article-title":"Hypertrophy of IMC of carotid artery in Parkinsons disease is associated with L-dopa, homocysteine, and MTHFR genotype.","volume":"207","author":"Nakaso","year":"2003","journal-title":"J Neurol Sci"},{"key":"R24-2-20210214","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000084302","article-title":"Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinsons disease in a Polish population.","volume":"53","author":"Bialecka","year":"2005","journal-title":"Eur Neurol"},{"key":"R25-2-20210214","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/bi00013a008","article-title":"Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the termolabile variant of the enzyme.","volume":"34","author":"Lotta","year":"1995","journal-title":"Biochemistry"},{"key":"R26-2-20210214","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1126\/science.1131262","article-title":"Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure.","volume":"314","author":"Nackley","year":"2006","journal-title":"Science"},{"key":"R27-2-20210214","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R28-2-20210214","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cca.2010.11.004","article-title":"Association of MTHFR, MTR, and MTRR polymorphisms with Parkinsons disease among ethnic Chinese in Taiwan.","volume":"412","author":"Fong","year":"2011","journal-title":"Clin Chim Acta"},{"key":"R29-2-20210214","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","article-title":"A clinicopathological study of 100 cases of Parkinsons disease.","volume":"50","author":"Hughes","year":"1993","journal-title":"Arch Neurol"},{"key":"R30-2-20210214","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression, and mortality.","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"R31-2-20210214","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state: a practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"R32-2-20210214","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression.","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"R33-2-20210214","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1212\/WNL.46.3.700","article-title":"Age and education correction of Mini-Mental State Examination for English and Spanish speaking elderly.","volume":"46","author":"Mungas","year":"1996","journal-title":"Neurology"},{"key":"R38-2-20210214","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria in Parkinsons disease associated with dementia.","volume":"12","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"key":"R39-2-20210214","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/FPC.0b013e328306c2f2","article-title":"The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinsons disease, levodopa treatment response, and complications.","volume":"18","author":"Bialecka","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R40-2-20210214","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2217\/14622416.8.11.1551","article-title":"677CT and 1298AC MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.","volume":"8","author":"Kurzawski","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R41-2-20210214","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/13547500903420203","article-title":"The SLC19A1 80GA polymorphism is not associated with male infertility.","volume":"15","author":"Kurzawski","year":"2010","journal-title":"Biomarkers"},{"key":"R42-2-20210214","first-page":"1","article-title":"A randomized controlled trial investigating the effect of vitamin B12 supplementation on neurological function in healthy older people: the Older People and Enhanced Neurological function (OPEN) study protocol ISRCTN54195799.","volume":"22","author":"Dangour","year":"2011","journal-title":"Nutr J"},{"key":"R43-2-20210214","first-page":"1","article-title":"Cognitive impairment and vitamin B12: a review.","volume":"6","author":"Moore","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"R44-2-20210214","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2796.2011.02484.x","article-title":"Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: a longitudinal study.","volume":"271","author":"Hooshmand","year":"2012","journal-title":"J Intern Med"},{"key":"R45-2-20210214","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1046\/j.1523-1755.63.s84.52.x","article-title":"Genetic determinants of the homocysteine level.","volume":"84","author":"Sunder-Plassmann","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"R46-2-20210214","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1681\/ASN.V11101918","article-title":"Effect of MTHFR 1298AC and MTHFR 677CT genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kidney graft recipients.","volume":"11","author":"Fodinger","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R47-2-20210214","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jns.2009.09.007","article-title":"Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinsons disease patients.","volume":"287","author":"Yuan","year":"2009","journal-title":"J Neurol Sci"},{"key":"R48-2-20210214","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S0140-6736(95)91743-8","article-title":"Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida.","volume":"21","author":"Van der Put","year":"1995","journal-title":"Lancet"},{"key":"R50-2-20210214","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jalz.2010.08.234","article-title":"Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants.","volume":"7","author":"Wald","year":"2011","journal-title":"Alzheimers Dement"},{"key":"R51-2-20210214","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/ajcn\/85.2.511","article-title":"Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging.","volume":"85","author":"Haan","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"R52-2-20210214","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jocn.2009.09.034","article-title":"L-dopa therapy increase homocysteine concentration in cerebrospinal fluid from patients with Parkinsons Disease.","volume":"17","author":"Isobe","year":"2010","journal-title":"J Clin Neurosci"},{"key":"R53-2-20210214","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1515\/CCLM.2005.193","article-title":"Plasma homocysteine levels in L-dopa-treated Parkinsons disease patients with cognitive dysfunctions.","volume":"43","author":"Zoccolella","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"R54-2-20210214","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/mds.23319","article-title":"Catechol-O-methyltransferase val158met and cognitive function in Parkinsons disease.","volume":"25","author":"Hoogland","year":"2010","journal-title":"Mov Disord"},{"key":"R55-2-20210214","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2011.242446","article-title":"Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia.","volume":"83","author":"Ford","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R56-2-20210214","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/mds.22227","article-title":"Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinsons disease patients.","volume":"24","author":"Camicioli","year":"2009","journal-title":"Mov Disord"},{"key":"R57-2-20210214","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neures.2010.06.011","article-title":"Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to Alzheimers disease.","volume":"68","author":"Zhang","year":"2010","journal-title":"Neurosci Res"},{"key":"R58-2-20210214","first-page":"1283","article-title":"On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis.","volume":"17","author":"Zhu","year":"2002","journal-title":"Histol Histopathol"},{"key":"R59-2-20210214","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1389200023337586","article-title":"Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis.","volume":"3","author":"Zhu","year":"2002","journal-title":"Curr Drug Metab"},{"key":"R60-2-20210214","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00702-004-0262-4","article-title":"The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.","volume":"112","author":"Nissinen","year":"2005","journal-title":"J Neural Transm"},{"key":"R61-2-20210214","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3940(00)01749-3","article-title":"Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinsons disease.","volume":"298","author":"Lee","year":"2001","journal-title":"Neurosci Lett"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-201210000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T09:08:21Z","timestamp":1714295301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201210000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e32835693f7","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}